Objective: To determine and quantify the unique characteristics of clinical trial participants in comparison to the general patient population.
♦ There has been much focus in the literature on barriers to participation in clinical trials, especially among cancer and HIV patients. [1] [2] ♦ Previous studies of clinical trial participation have reported a significantly lower likelihood of participation among patients from racial and ethnic minority groups and those with lower socioeconomic status including lower educational attainment, lower household income, and health insurance status. [3] [4] [5] [6] ♦ Disease progression, efficacy of current treatment, and co-morbid conditions also have been shown to affect patient willingness or ability to participate in a clinical trial and physician willingness or ability to suggest the possibility of participation. [6] [7] ♦ There is concern that these potential barriers to participation in a clinical trial may result in a sample that is unique and not representative of the total patient population. ♦ The therapeutic area of the trial was not specified.
Health-Related Quality of Life (HRQoL)
♦ HRQoL in the past four weeks was assessed using the Medical Outcomes Study (MOS) 8-item Short-Form Health Survey (SF-8). 8 ♦ The SF-8 is a generic 8-item health-related quality of life measure designed to assess physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. (Table 1) ♦ Clinical trial participants are more likely to be male, older, unmarried, and to have a college degree than the general patient population.
♦ Clinical trial participants are more likely to report drinking alcohol two or more times per week but are less likely to smoke cigarettes than the general patient population. (Table 2) ♦ Clinical trial participants are more likely to have used inpatient and outpatient resources in the past six months than the general patient population.
RESULTS (cont'd)
♦ Clinical trial participants also visited traditional and alternative providers significantly more frequently in the past six months. ♦ Because of these differences, the treatment experiences of clinical trial participants may not always be predictive of the treatment experiences of the general patient population.
♦ To increase the representativeness of clinical trial samples, barriers to participation must be removed. Identification of these barriers should help in the development of strategies to maximize participation in trials.
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